Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-9 PORT post-resection/ablation chemotherapy in metastatic colorectal cancer
2024-512174-10-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin, irinotecan and capecitabine in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Progression-free survival. Planned start Nov 2021; status: authorised.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecancapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-512174-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512174-10-00.